Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
First-line Nivo-Ipi therapy is effective in elderly patients with NSCLC. Although there was an increased incidence of pneumonitis, the treatment was manageable and presented as a viable treatment option. Notably, the occurrence of treatment-related AEs was associated with improved clinical outcomes, suggesting a potential prognostic value of AEs in this population.
Authors
- Hiroshi Kagamu (ORCID: https://orcid.org/0000-0003-4523-8517)
- Ayako Shiono (ORCID: https://orcid.org/0000-0001-6546-3864)
- Kasumi Tsukamoto
- Kunihiko Kobayashi (ORCID: https://orcid.org/0000-0002-6468-9068)
- Kyoichi Kaira (ORCID: https://orcid.org/0000-0001-5548-7686)
- Hisao Imai (ORCID: https://orcid.org/0000-0003-3097-4255)
- Ou Yamaguchi (ORCID: https://orcid.org/0000-0001-7194-6459)
- Kenji Masaki
- Junichi Nakagawa (ORCID: https://orcid.org/0000-0003-2340-2267)
- Kosuke Hashimoto (ORCID: https://orcid.org/0000-0001-7627-7901)
- Satoshi Endo (ORCID: https://orcid.org/0000-0002-8477-5553)
- Atsuto Mouri (ORCID: https://orcid.org/0000-0001-8704-8151)
- Yu Miura (ORCID: https://orcid.org/0000-0002-2752-5873)
Institutions
- National Hospital Organization Takasaki Medical Center (JP)
- Gunma Prefectural Cardiovascular Center (JP)
- National Hospital Organization (JP)
- Gunma Children's Medical Center (JP)
- National Disaster Medical Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-01-23
- DOI
- https://doi.org/10.1007/s00432-025-06089-x
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09